When opioid cravings hit — especially in the early hours and days of detox — they don’t feel like a mild preference. They feel like an emergency. Every part of the brain that has been rewired around opioid use is demanding relief, and the physical symptoms of withdrawal make that demand feel even more urgent.
This is exactly why medication-assisted treatment during opioid detox isn’t a shortcut or a crutch. It’s a clinically essential tool — one that makes it possible for people to get through the most biologically driven period of early recovery and into the therapeutic work that sustains long-term sobriety.
So what medications actually work? How quickly do they work? And what do they do in the body that makes such a significant difference?
First: What “Immediately” Actually Means
Let’s be honest about the word “immediately” — because it matters clinically.
No medication stops opioid cravings in an absolute, instantaneous sense. Cravings are a complex neurobiological phenomenon involving multiple brain systems — the reward pathways, the stress-response systems, the conditioned associations between environmental cues and the expectation of opioids. A single medication can significantly reduce craving intensity and the physical distress of withdrawal, but the process of full neurological recalibration takes days, weeks, and months.
That said, some medications — particularly buprenorphine — can produce meaningful, rapid relief within 30 to 60 minutes of administration. In the context of acute opioid withdrawal, that’s the closest thing to “immediate” that exists clinically. And for someone in the throes of withdrawal, that window of relief is genuinely significant.
With that framing in place, here are the medications that make the biggest difference in opioid detox — what they are, how they work, and what to expect.
Buprenorphine: The Fastest-Acting and Most Widely Used
Buprenorphine — sold under brand names including Suboxone, Subutex, Sublocade, and Brixadi — is the medication most commonly used to manage opioid withdrawal and cravings during detox, and for good reason. It is a partial opioid agonist, meaning it binds to the same opioid receptors in the brain that heroin, fentanyl, oxycodone, and other opioids act on — but it activates those receptors only partially, producing enough effect to relieve withdrawal symptoms and reduce cravings without producing the euphoric high of a full agonist.
According to NIDA, buprenorphine reduces withdrawal symptoms and drug cravings while having a ceiling effect on its opioid activity — meaning that beyond a certain dose, increasing the amount doesn’t produce additional opioid effects. This ceiling effect makes buprenorphine significantly safer than methadone in terms of overdose risk.
How quickly does it work? When administered sublingually — dissolved under the tongue, as the most common formulations are used — buprenorphine typically begins to reduce withdrawal symptoms and cravings within 30 to 60 minutes. Most people experience meaningful relief within the first hour of the first dose.
Important clinical consideration. Buprenorphine must be initiated carefully. Because it is a partial agonist with high receptor affinity, administering it while full agonist opioids are still significantly occupying the receptors can precipitate a sudden, severe withdrawal — a condition called precipitated withdrawal. Standard clinical protocols require waiting until a person is in mild to moderate withdrawal before administering the first dose. In a medically supervised detox setting, clinicians use validated assessment tools — including the Clinical Opiate Withdrawal Scale (COWS) — to determine the right timing for initiation.
Suboxone, the most common buprenorphine formulation, also contains naloxone — an opioid antagonist added specifically to deter misuse. When taken as prescribed sublingually, the naloxone is minimally absorbed and has little effect. If someone attempts to inject the medication, the naloxone is absorbed systemically and precipitates immediate withdrawal — a deliberate safety feature.
Methadone: Powerful, Effective, and Highly Regulated
Methadone is a full opioid agonist — it binds to opioid receptors completely and activates them. As a result, it is highly effective at eliminating opioid cravings and withdrawal symptoms, often within a few hours of the first dose.
NIDA’s clinical guidance notes that methadone has been used for more than 50 years to treat opioid use disorder. It works by binding opioid receptors more slowly than drugs like heroin or fentanyl and remaining in the body for a longer period — producing a stable, sustained effect that reduces cravings without the peaks and crashes that drive addictive cycles.
The critical difference between methadone and buprenorphine for most people seeking private residential detox is the regulatory context. In the United States, methadone for opioid use disorder can only be dispensed from specially licensed opioid treatment programs — not in standard residential detox settings and not in private office-based practice. Buprenorphine, by contrast, can be prescribed and administered in a much wider range of settings, including private residential detox programs.
This means that for people entering private residential detox, buprenorphine is significantly more likely to be the medication available for withdrawal management and craving reduction.
Naltrexone: A Different Mechanism, a Different Timeline
Naltrexone — sold as Vivitrol in its long-acting injectable form — works through a fundamentally different mechanism than buprenorphine or methadone. Rather than activating opioid receptors to relieve withdrawal, naltrexone blocks them entirely. It is a full opioid antagonist — meaning it occupies opioid receptors without activating them, preventing any opioid from producing its effects.
The critical implication of this mechanism: naltrexone does not relieve acute withdrawal symptoms, and it is not administered during the active detox phase. Because it blocks opioid receptors, administering naltrexone while opioids are still in the system would precipitate immediate, severe withdrawal. NIDA notes that a person typically needs to stop taking opioids for 7 to 10 days before starting naltrexone treatment.
Naltrexone’s role is post-detox — as a maintenance medication that removes the reinforcing properties of opioids, making relapse less rewarding and supporting long-term abstinence. The monthly injectable form (Vivitrol) is particularly useful for people whose adherence to daily oral medication would otherwise be unreliable.
A 2024 NIDA-supported study found that a faster approach for initiating extended-release naltrexone — reducing the opioid-free period using a structured buprenorphine bridge protocol — significantly increased the proportion of patients who successfully received their first naltrexone injection (62.7% vs. 35.8% with the standard approach). This research is actively reshaping how clinicians sequence MOUD medications in detox.
Lofexidine and Clonidine: Targeting Withdrawal Symptoms Without Opioid Receptors
Lofexidine (brand name Lucemyra) and clonidine are non-opioid medications that address a specific dimension of opioid withdrawal — the noradrenergic hyperactivity that drives many of the most physically miserable symptoms: racing heart, sweating, chills, anxiety, muscle aches, and agitation.
When opioids are removed, the locus coeruleus — a brain region responsible for regulating the stress-response and arousal systems — becomes overactive, flooding the body with norepinephrine and producing the constellation of physical symptoms that make withdrawal so difficult to endure. Lofexidine and clonidine are alpha-2 adrenergic agonists — they calm this overactivity by reducing norepinephrine release, providing meaningful relief from the physical symptoms of withdrawal.
NIDA’s research profile on MOUD identifies lofexidine as approved specifically for the treatment of acute opioid withdrawal symptoms, for up to 14 days. Unlike buprenorphine and methadone, lofexidine does not act on opioid receptors — which means it doesn’t carry the regulatory complexity or the precipitated withdrawal risk of agonist medications. It also means it doesn’t reduce cravings with the same directness as buprenorphine — it addresses the physical symptoms of withdrawal more than the craving itself.
Lofexidine is often used in combination with other medications during detox — particularly to support the bridge to naltrexone in people who prefer a non-opioid approach to withdrawal management.
Clonidine is an older medication in the same class as lofexidine — used off-label for opioid withdrawal for decades. It is generally less preferred in contemporary clinical protocols because of its tendency to cause significant blood pressure reduction compared to lofexidine, but remains in use, particularly in settings where lofexidine isn’t available.
Why Medically Supervised Detox Is Essential for MOUD
Understanding these medications matters — but it’s equally important to understand that they are clinical tools, not home remedies. Each one requires individualized assessment, careful timing, appropriate dosing, and monitoring for side effects and complications that can only be provided in a clinical setting.
Buprenorphine initiation timing is a clinical decision that requires withdrawal assessment — getting it wrong can precipitate severe withdrawal. Methadone dosing requires careful titration to avoid toxicity. Naltrexone initiation requires a confirmed opioid-free period. Lofexidine affects blood pressure and requires monitoring.
In a medically supervised detox program, these medications are administered within a comprehensive clinical protocol — with around-the-clock monitoring, dose adjustments based on real-time symptom assessment, and the safety of a clinical team present to respond to any complications. MedlinePlus is clear on this point: these medications restore balance to the parts of the brain affected by addiction, allowing the brain to heal while the person works toward recovery — but that healing process is best supported within a structured, monitored clinical environment.
Attempting to obtain and self-administer these medications outside of a medical context is not only clinically risky — it misses the point. The medications are most effective as part of a comprehensive, individualized treatment plan that begins with medically supervised detox and transitions into the therapeutic work of residential treatment.
Getting the Right Medications in the Right Setting
If you or someone you love is dependent on opioids and ready to start the detox process, the most important first step is connecting with a medically supervised detox program that has experience with MOUD — and that can administer the right medications, at the right time, with the right clinical oversight.
New Beginnings Recovery in Rancho Mirage provides medically supervised detox with individualized medication management, 24/7 clinical monitoring, and a direct pathway into residential treatment — giving you the best possible foundation for recovery from opioid dependence.
Our admissions team is available around the clock at (760) 924-9419, or you can reach out online at any time. Insurance verification takes just a few minutes.
The right medications exist. The right clinical support exists. Let us help you access both.
New Beginnings Recovery is a private detox and residential treatment program located in Rancho Mirage, California, serving individuals and families across Palm Springs and the Coachella Valley.